Attenuation of hormone responses to the 5-HT1A agonist ipsapirone by long-term treatment with fluoxetine, but not desipramine, in male rats

Qian Li, Brownfield Mark S., Andrew D. Levy, George Battaglia, Theresa M. Cabrera, Louis D. Van de Kar

Research output: Contribution to journalArticle

Abstract

The present study had two objectives: (1) to provide information on neuroendocrine challenge tests that can lead to diagnostic tests in humans; and (2) to confirm our previous observation that chronic fluoxetine selectively inhibits serotonin (5-HT1A) receptor function. We determined the effect of chronic fluoxetine and desipramine (DMI) on the hormone response to ipsapirone, a 5-HT1A agonist and a potential anxiolytic drug. Ipsapirone increased oxytocin, adrenocorticotropic hormone (ACTH), corticosterone, and prolactin, but not renin or vasopressin concentrations in plasma. Chronic fluoxetine, but not DMI, significantly inhibited the effect of ipsapirone on plasma oxytocin, ACTH and corticosterone concentrations. Chronic fluoxetine also reduced the Bmax for 3H-8-hydroxy-2-(dipropylamino) tetralin (3H-8-OH-DPAT) labelled 5-HT1A receptors in the midbrain. Neither antidepressant altered the density or affinity of 5-HT uptake sites. In conclusion, the present results confirm our previous results using 8-OH-DPAT as a challenge, and suggest that chronic 5-HT uptake inhibition results in adaptive changes leading to decreased function of the 5-HT1A receptor system. Finally, because ipsapirone may be administered to humans, it might be usable to evaluate 5-HT1A receptor function in depressed patients.

Original languageEnglish (US)
Pages (from-to)300-308
Number of pages9
JournalBiological Psychiatry
Volume36
Issue number5
DOIs
StatePublished - Sep 1 1994
Externally publishedYes

Fingerprint

Serotonin 5-HT1 Receptor Agonists
Receptor, Serotonin, 5-HT1A
Desipramine
Fluoxetine
Hormones
8-Hydroxy-2-(di-n-propylamino)tetralin
Oxytocin
Corticosterone
Adrenocorticotropic Hormone
Serotonin
Anti-Anxiety Agents
Therapeutics
Mesencephalon
Vasopressins
Routine Diagnostic Tests
Renin
Prolactin
Antidepressive Agents
ipsapirone
Pharmaceutical Preparations

Keywords

  • ACTH
  • antidepressants
  • oxytocin
  • prolactin
  • renin
  • Serotonin
  • vasopressin

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Attenuation of hormone responses to the 5-HT1A agonist ipsapirone by long-term treatment with fluoxetine, but not desipramine, in male rats. / Li, Qian; Mark S., Brownfield; Levy, Andrew D.; Battaglia, George; Cabrera, Theresa M.; Van de Kar, Louis D.

In: Biological Psychiatry, Vol. 36, No. 5, 01.09.1994, p. 300-308.

Research output: Contribution to journalArticle

Li, Qian ; Mark S., Brownfield ; Levy, Andrew D. ; Battaglia, George ; Cabrera, Theresa M. ; Van de Kar, Louis D. / Attenuation of hormone responses to the 5-HT1A agonist ipsapirone by long-term treatment with fluoxetine, but not desipramine, in male rats. In: Biological Psychiatry. 1994 ; Vol. 36, No. 5. pp. 300-308.
@article{b36cd88083244c8b8b18af2d382a081b,
title = "Attenuation of hormone responses to the 5-HT1A agonist ipsapirone by long-term treatment with fluoxetine, but not desipramine, in male rats",
abstract = "The present study had two objectives: (1) to provide information on neuroendocrine challenge tests that can lead to diagnostic tests in humans; and (2) to confirm our previous observation that chronic fluoxetine selectively inhibits serotonin (5-HT1A) receptor function. We determined the effect of chronic fluoxetine and desipramine (DMI) on the hormone response to ipsapirone, a 5-HT1A agonist and a potential anxiolytic drug. Ipsapirone increased oxytocin, adrenocorticotropic hormone (ACTH), corticosterone, and prolactin, but not renin or vasopressin concentrations in plasma. Chronic fluoxetine, but not DMI, significantly inhibited the effect of ipsapirone on plasma oxytocin, ACTH and corticosterone concentrations. Chronic fluoxetine also reduced the Bmax for 3H-8-hydroxy-2-(dipropylamino) tetralin (3H-8-OH-DPAT) labelled 5-HT1A receptors in the midbrain. Neither antidepressant altered the density or affinity of 5-HT uptake sites. In conclusion, the present results confirm our previous results using 8-OH-DPAT as a challenge, and suggest that chronic 5-HT uptake inhibition results in adaptive changes leading to decreased function of the 5-HT1A receptor system. Finally, because ipsapirone may be administered to humans, it might be usable to evaluate 5-HT1A receptor function in depressed patients.",
keywords = "ACTH, antidepressants, oxytocin, prolactin, renin, Serotonin, vasopressin",
author = "Qian Li and {Mark S.}, Brownfield and Levy, {Andrew D.} and George Battaglia and Cabrera, {Theresa M.} and {Van de Kar}, {Louis D.}",
year = "1994",
month = "9",
day = "1",
doi = "10.1016/0006-3223(94)90627-0",
language = "English (US)",
volume = "36",
pages = "300--308",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Attenuation of hormone responses to the 5-HT1A agonist ipsapirone by long-term treatment with fluoxetine, but not desipramine, in male rats

AU - Li, Qian

AU - Mark S., Brownfield

AU - Levy, Andrew D.

AU - Battaglia, George

AU - Cabrera, Theresa M.

AU - Van de Kar, Louis D.

PY - 1994/9/1

Y1 - 1994/9/1

N2 - The present study had two objectives: (1) to provide information on neuroendocrine challenge tests that can lead to diagnostic tests in humans; and (2) to confirm our previous observation that chronic fluoxetine selectively inhibits serotonin (5-HT1A) receptor function. We determined the effect of chronic fluoxetine and desipramine (DMI) on the hormone response to ipsapirone, a 5-HT1A agonist and a potential anxiolytic drug. Ipsapirone increased oxytocin, adrenocorticotropic hormone (ACTH), corticosterone, and prolactin, but not renin or vasopressin concentrations in plasma. Chronic fluoxetine, but not DMI, significantly inhibited the effect of ipsapirone on plasma oxytocin, ACTH and corticosterone concentrations. Chronic fluoxetine also reduced the Bmax for 3H-8-hydroxy-2-(dipropylamino) tetralin (3H-8-OH-DPAT) labelled 5-HT1A receptors in the midbrain. Neither antidepressant altered the density or affinity of 5-HT uptake sites. In conclusion, the present results confirm our previous results using 8-OH-DPAT as a challenge, and suggest that chronic 5-HT uptake inhibition results in adaptive changes leading to decreased function of the 5-HT1A receptor system. Finally, because ipsapirone may be administered to humans, it might be usable to evaluate 5-HT1A receptor function in depressed patients.

AB - The present study had two objectives: (1) to provide information on neuroendocrine challenge tests that can lead to diagnostic tests in humans; and (2) to confirm our previous observation that chronic fluoxetine selectively inhibits serotonin (5-HT1A) receptor function. We determined the effect of chronic fluoxetine and desipramine (DMI) on the hormone response to ipsapirone, a 5-HT1A agonist and a potential anxiolytic drug. Ipsapirone increased oxytocin, adrenocorticotropic hormone (ACTH), corticosterone, and prolactin, but not renin or vasopressin concentrations in plasma. Chronic fluoxetine, but not DMI, significantly inhibited the effect of ipsapirone on plasma oxytocin, ACTH and corticosterone concentrations. Chronic fluoxetine also reduced the Bmax for 3H-8-hydroxy-2-(dipropylamino) tetralin (3H-8-OH-DPAT) labelled 5-HT1A receptors in the midbrain. Neither antidepressant altered the density or affinity of 5-HT uptake sites. In conclusion, the present results confirm our previous results using 8-OH-DPAT as a challenge, and suggest that chronic 5-HT uptake inhibition results in adaptive changes leading to decreased function of the 5-HT1A receptor system. Finally, because ipsapirone may be administered to humans, it might be usable to evaluate 5-HT1A receptor function in depressed patients.

KW - ACTH

KW - antidepressants

KW - oxytocin

KW - prolactin

KW - renin

KW - Serotonin

KW - vasopressin

UR - http://www.scopus.com/inward/record.url?scp=0027958882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027958882&partnerID=8YFLogxK

U2 - 10.1016/0006-3223(94)90627-0

DO - 10.1016/0006-3223(94)90627-0

M3 - Article

VL - 36

SP - 300

EP - 308

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 5

ER -